| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Definium Therapeutics, Inc. (DFTX) has 4 insiders with recent SEC Form 4 filings, including 0 buys and 3 sells. DFTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 752.5K | $16.56M | - | |
| Other | 413.3K | $9.10M | - | |
| Other | 271.1K | $5.97M | - | |
| Dir | 50.0K | $1.10M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Karlin Daniel | Chief Medical Officer | Sell | 8,018 | $18.47 | $148,092.46 | -1.9% | - | - | |
| Mar 25, 2026 | Barrow Robert | Chief Executive Officer | Sell | 24,431 | $18.47 | $451,240.57 | -3.1% | - | - | |
| Mar 25, 2026 | Sullivan Mark | Chief Legal Officer | Sell | 10,702 | $18.47 | $197,665.94 | -3.8% | - | - |